| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/10/2009 | US20090226405 COMPOSITIONS AND METHODS TO TREAT CANCER WITH CUPREDOXINS AND CpG RICH DNA |
| 09/10/2009 | US20090226403 Olfactory and pheromones G-protein coupled receptors |
| 09/10/2009 | US20090226400 Continuous delivery methods for treating hepatitis virus infection |
| 09/10/2009 | US20090226399 Medicaments comprising gene recombinant antibody against ganglioside gd3 |
| 09/10/2009 | US20090226398 Anti-viral compounds, compositions, and methods of use |
| 09/10/2009 | US20090226397 Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination |
| 09/10/2009 | US20090226396 Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| 09/10/2009 | US20090226387 Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation |
| 09/10/2009 | US20090226370 GEP, a novel chondrogenic growth factor and target in cartilage disorders |
| 09/10/2009 | US20090226369 STQ Peptides |
| 09/09/2009 | EP2098595A1 Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
| 09/09/2009 | EP2098245A1 Use of cholinesterase for manufacturing an anti-tachykinins medicament |
| 09/09/2009 | EP2098244A1 Pharmaceutical composition for the treatment of myocardial infarction |
| 09/09/2009 | EP2098243A1 G-CSF liquid formulation |
| 09/09/2009 | EP2098242A1 MCH derived peptide-containing food intake regulator |
| 09/09/2009 | EP2097526A2 Expression system of nell peptide |
| 09/09/2009 | EP2097520A1 A method for producing n-terminal methioine free polypeptides in microbial host cells |
| 09/09/2009 | EP2097440A1 Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections |
| 09/09/2009 | EP2097439A1 Novel peptides |
| 09/09/2009 | EP2097110A2 Biological pacemakers including mutated hyperpolarization-activated cyclic nucleotide-gated (hcn) channels |
| 09/09/2009 | EP2097096A1 Modified coagulation factors with prolonged in vivo half-life |
| 09/09/2009 | EP2097095A2 Myostatin inhibition for enhancing muscle and/or improving muscle function |
| 09/09/2009 | EP2097093A2 Therapeutic and diagnostic peptides |
| 09/09/2009 | EP2097092A2 Modulation of rhamm (cd168) for selective adipose tissue development |
| 09/09/2009 | EP2097091A2 Conjugate of natriuretic peptide and antibody constant region |
| 09/09/2009 | EP2097090A2 Peptide and treatment for hiv-1 infection |
| 09/09/2009 | EP2097087A2 Suppressive macrophages, c-reactive protein and the treatment of systemic lupus erythematosus and immune thrombocytopenic purpura |
| 09/09/2009 | EP2097068A2 Formulations of peg-interferon alpha conjugates |
| 09/09/2009 | EP2097066A2 Microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics |
| 09/09/2009 | EP2096914A2 Poly-tlr antagonist |
| 09/09/2009 | EP1909813A4 Peptidyl diacylglycerides |
| 09/09/2009 | EP1846013A4 Treatment of skin diseases |
| 09/09/2009 | EP1802653B1 Mam domain containing protein |
| 09/09/2009 | EP1734979A4 Follicle stimulating hormone superagonists |
| 09/09/2009 | EP1654272B1 Ra antigenic peptides |
| 09/09/2009 | EP1651248B1 Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form |
| 09/09/2009 | EP1648925B1 Bicyclic peptide imaging agents |
| 09/09/2009 | EP1644410B1 Sushi peptide multimer |
| 09/09/2009 | EP1548028B1 Substituted type peptides of wt1 |
| 09/09/2009 | EP1536821A4 Inhibition of t cell activation by butyrophilin 4 or b7-l1 |
| 09/09/2009 | EP1517918B9 Peptides having affinity for a phospholipid and uses |
| 09/09/2009 | EP1509621B1 Diagnostic of alzheimer's disease by analysis of il-10 gene polymorphisms |
| 09/09/2009 | EP1446733B1 Glycosylphosphatidylinositol containing polypeptides |
| 09/09/2009 | EP1389219B1 Dimerized t-cell receptor fragment, its compositions and use |
| 09/09/2009 | EP1379270B1 Use of anti-cd3 monoclonal antibodies and il-5 for treating autoimmune diseases |
| 09/09/2009 | EP1290027B1 Immunoadhesin for the prevention of rhinovirus infection |
| 09/09/2009 | EP1165096B1 Use of cytidine derivatives for the treatment of leukaemia |
| 09/09/2009 | EP1098962B1 Diacylglycerol acyl transferase proteins |
| 09/09/2009 | EP1033971B1 Combined chemo-immunotherapy with liposomal drugs and cytokines |
| 09/09/2009 | EP1015488B1 Interleukin-17 receptor-like protein |
| 09/09/2009 | EP0996857B1 Cancer associated nucleic acids and polypeptides |
| 09/09/2009 | EP0861261B1 Nucleotide and protein sequences of vertebrate delta genes and methods based thereon |
| 09/09/2009 | EP0817847B2 Il-17 receptor |
| 09/09/2009 | EP0813545B1 Nucleotide and protein sequences of vertebrate serrate genes and methods based thereon |
| 09/09/2009 | EP0771147B1 Compositions and methods for enhanced tumor cell immunity in vivo |
| 09/09/2009 | CN101528925A Dbait and uses thereof |
| 09/09/2009 | CN101528253A Antimicrobial composition and uses thereof |
| 09/09/2009 | CN101528252A Use of IL-1 antagonists to treat gout and pseudogout |
| 09/09/2009 | CN101528251A Agent comprising G-CSF for prevention and treatment of diabetic peripheral neuropathy |
| 09/09/2009 | CN101528250A Ligands of melanocortin receptors |
| 09/09/2009 | CN101528249A Sustained release formulations comprising very low molecular weight polymers |
| 09/09/2009 | CN101528248A Antimicrobial peptides |
| 09/09/2009 | CN101528247A Sequential combination therapy |
| 09/09/2009 | CN101528246A Composition to treat and/or prevent gastrointestinal infection |
| 09/09/2009 | CN101525617A Eriocheir sinensis Crustin-1 gene and in-vitro recombination expression |
| 09/09/2009 | CN101525616A Preparation and application of sperm binding protein HEL-127 specifically expressed in human epididymis |
| 09/09/2009 | CN101525615A Defensins gene expressed in human epididymis, and cloning, expression and application of same |
| 09/09/2009 | CN101525611A Fusarium plasmin and preparation method thereof |
| 09/09/2009 | CN101525610A Application of earthworm fibronectin enzyme in treating hepatitis B |
| 09/09/2009 | CN101525598A Method for purifying human urinary trypsin inhibitor |
| 09/09/2009 | CN101525388A Specific double-strand RNA binding protein chimera and application thereof in virus infectious diseases |
| 09/09/2009 | CN101525386A Fusion protein of Exendin-4 tandem polypeptide and human serum albumin, preparation and application thereof |
| 09/09/2009 | CN101525374A Pentapeptide derivative, preparation method and applications thereof |
| 09/09/2009 | CN101525373A Inhibitor of TGF-beta activation reaction |
| 09/09/2009 | CN101524531A Preparation and application of pharmaceutical composition containing collagen and isosorbide mononitrate |
| 09/09/2009 | CN101524530A The treatment of diabetes |
| 09/09/2009 | CN101524529A Treatment on human malignant solid tumor by HNF4 alpha inducement and differentiation |
| 09/09/2009 | CN101524528A Recombination NuBCP-9 and Tumstatin(74-98) antitumor fusion polypetide |
| 09/09/2009 | CN101524527A TAT-HOXB4H fusion protein used as hematopoiesis irritant and the pharmaceutical composition thereof |
| 09/09/2009 | CN101524526A New application of LSECtin |
| 09/09/2009 | CN101524351A Treating infectious diseases by administering an ICE inhibitor |
| 09/09/2009 | CN100537770C Von willebrand factor (vWF)-cleaving enzyme |
| 09/09/2009 | CN100537602C EC SOD and cell transducing EC SOD and use thereof |
| 09/09/2009 | CN100537598C Substantially crystalline form of melagatran |
| 09/09/2009 | CN100536922C Polymeric delivery formulations of leuprolide with improved efficacy |
| 09/09/2009 | CN100536919C Interferon antagon and usage of Flt3L antagon |
| 09/09/2009 | CN100536916C Novel usage of human antalzyme in the process for preparing ophthalmopathy treating medicine |
| 09/09/2009 | CN100536915C 神经毒素植入物 Neurotoxin implant |
| 09/09/2009 | CN100536914C Anti-oxidation, anti-senium oyster product and its preparation method |
| 09/09/2009 | CN100536913C Method for preparing insulin capsule |
| 09/09/2009 | CN100536912C Use of HCG in controlled ovarian hyperstimulation |
| 09/09/2009 | CN100536911C Peptide composition |
| 09/09/2009 | CN100536910C Thymosin alpha 1 peptide/polymer conjugates |
| 09/09/2009 | CN100536909C Methods for preventing mitochondrial permeability transition |
| 09/09/2009 | CN100536853C Ss-l-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies |
| 09/09/2009 | CN100536852C Application of L-FMAU for preparation of medicament for combination therapies of hepatitis b virus infection |
| 09/08/2009 | USRE40911 Canine erythropoietin gene and recombinant protein |
| 09/08/2009 | US7585976 chemical intermediate for Hemiasterlin, first isolated from the sponge Hemiasterella; anticarcinogenic agent for treatment of colon cancer, tumor; prevention of restenosis of blood vessels subject to traumas such as angioplasty and stenting |
| 09/08/2009 | US7585967 DNA or RNA having a modified backbone or base and a section that hybridizes to an EphrinB2 or EphB4 transcript causing gene expression inhibition; antineoplastic and antiproliferative agents can be synergistically administered with a second agent |
| 09/08/2009 | US7585966 Directed against accessible regions in the telomerase ribonucleoprotein; cancer |